Welling­ton lines up a $393M bankroll for its next round of pri­vate biotech bets — and they’re like­ly think­ing big

Welling­ton Man­age­ment made some un­cus­tom­ary waves at the be­gin­ning of the year when it threw its con­sid­er­able weight against Bris­tol-My­ers Squibb’s $74 bil­lion Cel­gene buy­out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.